Currently, there are 49.08M common shares owned by the public and among those 38.00M shares have been available to trade.
The company’s stock has a 5-day price change of 7.39% and -13.45% over the past three months. BASE shares are trading -12.88% year to date (YTD), with the 12-month market performance up to 21.41% higher. It has a 12-month low price of $14.12 and touched a high of $32.00 over the same period. BASE has an average intraday trading volume of 489.00K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.49%, 8.25%, and -13.13% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Couchbase Inc (NASDAQ: BASE) shares accounts for 73.73% of the company’s 49.08M shares outstanding.
It has a market capitalization of $987.08M and a beta (3y monthly) value of 0.61. The earnings-per-share (ttm) stands at -$1.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.32% over the week and 3.63% over the month.
Earnings per share for the fiscal year are expected to increase by 33.59%, and 52.39% over the next financial year.
Looking at the support for the BASE, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on August 16, 2024, with the firm’s price target at $22. Needham coverage for the Couchbase Inc (BASE) stock in a research note released on June 26, 2024 offered a Buy rating with a price target of $22. Goldman was of a view on June 06, 2024 that the stock is Sell, while UBS gave the stock Neutral rating on May 22, 2024, issuing a price target of $31. Barclays on their part issued Equal Weight rating on February 20, 2024.
